Dr. Laviero Michael Mancinelli, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-2486 |
Linda Chui Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-2627 |
Laurie Ayano Higashi, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-2000 |
Marissa Nicole Chan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 510-752-4148 |
Albert Lee, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2238 Westborough Blvd, South San Francisco, CA 94080 Phone: 650-873-0551 |
Erica Tung Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 El Camino Real, South San Francisco, CA 94080 Phone: 650-742-3251 |
Dr. Bill M. Wong, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 451 South Airport Blvd, South San Francisco, CA 94080 Phone: 650-872-0637 |
Mrs. Sharon Cheong-wong, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2238 Westborough Blvd, South San Francisco, CA 94080 Phone: 650-873-0551 Fax: 650-873-0234 |
News Archive
Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors' report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at www.dyadic.com.
High blood cholesterol, a serious hereditary disease, is far more common than previously recognised and not treated sufficiently.
Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.
For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
› Verified 2 days ago